Novavax (NVAX) Revenue Growth (5y) (2015 - 2026)
Novavax (NVAX) Revenue Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,042.03 Bn | 67,041.74 Bn | - |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - |
| 4 | BeOne Medicines | 472.89 Bn | 468.10 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.12 Bn | 114.87 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.04 Bn | 61.29 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - |
| 8 | Argenx Se | 55.90 Bn | 50.72 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.47 Bn | 34.46 Bn | 959.66 Mn |
| 10 | Novavax | 1.25 Bn | 455.46 Mn | 108.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -20.78% |
| Dec 31, 2025 | -12.05% |
| Sep 30, 2025 | -14.81% |
| Jun 30, 2025 | 37.55% |
| Mar 31, 2025 | 187.79% |
| Dec 31, 2024 | 58.54% |
| Sep 30, 2024 | 102.09% |
| Jun 30, 2024 | 162.13% |
| Mar 31, 2024 | 88.14% |
| Dec 31, 2023 | 116.49% |
| Sep 30, 2023 | 89.09% |
| Jun 30, 2023 | 108.49% |
| Mar 31, 2023 | 53.01% |
| Dec 31, 2022 | 102.83% |
| Sep 30, 2022 | 144.82% |
| Jun 30, 2022 | 94.20% |
| Mar 31, 2022 | 162.21% |
| Dec 31, 2021 | 110.32% |
| Sep 30, 2021 | 78.19% |
| Jun 30, 2021 | 127.41% |